Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

By J. Burger, A. Tedeschi, P. Barr, T. Robak, C. Owen, P. Ghia, O. Bairey, P. Hillmen, N. Bartlett, Jianyong Li and 24 more. New England Journal of Medicine, 2015

1,457 citations recorded by the source corpus.

BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trial to compare two oral agents, ibrutinib and chlorambucil, in previously untreated older patients with CLL or small lymphocytic lymphoma. METHODS We randomly assigned 269 previously untreated patients who were 65 years of age or older and had CLL or small lymphocytic lymphoma to receive ibrutinib or chlorambucil. The primary end point was progression-free survival as assessed by an independent review committee. RESULTS The median age of the patients was 73 years. During a median follow-up period of 18.4 months, ibrutinib resulted in significantly longer progression-free survival than did chlorambucil (median, not reached vs. 18.9 months), with a risk of progression or death that was 84% lower with ibrutinib than that with chlorambucil (hazard ratio, 0.16; P<0.001). Ibrutinib significantly prolonged overall survival; the estimated survival rate at 24 months was 98% with ibrutinib versus 85% with chlorambucil, with a relative risk of death that was 84% lower in the ibrutinib group than in the chlorambucil group (hazard ratio, 0.16; P=0.001). The overall response rate was higher with ibrutinib than with chlorambucil (86% vs. 35%, P<0.001). The rates of sustained increases from baseline values in the hemoglobin and platelet levels were higher with ibrutinib. Adverse events of any grade that occurred in at least 20% of the patients receiving ibrutinib included diarrhea, fatigue, cough, and nausea; adverse events occurring in at least 20% of those receiving chlorambucil included nausea, fatigue, neutropenia, anemia, and vomiting. In the ibrutinib group, four patients had a grade 3 hemorrhage and one had a grade 4 hemorrhage. A total of 87% of the patients in the ibrutinib group are continuing to take ibrutinib. CONCLUSIONS Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematologic variables. (Funded by Pharmacyclics and others; RESONATE-2 ClinicalTrials.gov number, NCT01722487.)

Subfields: Genetics, Immunology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/3a9eb1c67d814e1dc4f2d49f148bb7b52fce1177

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

C. Turtle
K. Hay
L. Hanafi
Simar Pal Singh
Daniel H. Li
Floris Dammeijer
R. Hendriks
S. Cherian

Citations in the corpus

Role of Bruton’s tyrosine kinase in B cells and malignancies (2018, background): “TN CLL Ibrutinib III ORR (86%), CR(4%) [13]”
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. (2017, background): “For patients able to tolerate aggressive therapy, chemo-immunotherapy has been the preferred approach(4); however, recently, the Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, was approved, initially for relapsed and refractory disease and subsequently for firstline therapy.(5,6) Although the ”